Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific microbial members of the microbiota is challenging, because clinically detectable inflammation and its treatment can alter the microbiota's composition. Immunologic checkpoint blockade with ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signalling, is associated with new-onset, immune-mediated colitis. Here we conduct a prospective study of patients with metastatic melanoma undergoing ipilimumab treatment and correlate the pre-inflammation faecal microbiota and microbiome composition with subsequent colitis development. We demonstrate that increased representation of bacteria belonging to the Bacteroidetes phylum is correlated with resistance to the development of checkpoint-blockade-induced colitis. Furthermore, a paucity of genetic pathways involved in polyamine transport and B vitamin biosynthesis is associated with an increased risk of colitis. Identification of these biomarkers may enable interventions to reduce the risk of inflammatory complications following cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In parallel to microbial therapeutics, microbial signatures are being evaluated as a novel class of biomarkers, applied for stratification of efficacy and safety in clinical trials across multiple indications (Ananthakrishnan et al., 2017; Dubin et al., 2016).”
From Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers (2021) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The capacity of the microbiome to generate polyamines has also been associated with reduced toxicity of antibody to CTLA-4 in melanoma patients (22).”
From The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“differences may be related to several different factors – including differences in techniques used to analyze samples and reference databases used for analysis – which varied widely across the studies”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CTLA-4 blockade (alone or in combination with anti-PD-1/PD-L1) produces toxicities in a dose-dependent fashion.22,23”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, there is evidence that the microbiome is associated with development of immune-related adverse events (irAEs) following ICB7–9.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [8]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Self-citationAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationUCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Metagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699
Cited by
Items 901–991 of 991
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors
Villalona-Calero, M. A., Diaz, J. P., Duan, W., Diaz, Z., Schroeder, E. D., Aparo, S., Gatcliffe, T. A., Albrecht, F., Venkatappa, S. A., Guardiola, V., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00386-0 · Cited by 2
Cancer therapeutics and gut microflora
Ahlawat, S., Asha, A., & Sharma, K. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96128-8.00005-5
Thomas, A. S., & Wang, Y. (2022) · Springer eBooks · doi:10.1007/978-3-031-00241-0_5 · Cited by 1
Recent Developments Related to the Toxic Side Effects of Immunosuppressive Combination Therapy
费, 鹏. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.1281053
Immunotherapy in gynecologic malignancies
Renz, M., & Dorigo, O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-77684-4.00026-x · Cited by 1
Pianko, M. J. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2148219
周, 会. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.12121574
Gut Microbiome and Immune Responses in Gastrointestinal Cancer
Laube, R., & Liu, K. (2023) · Springer eBooks · doi:10.1007/978-981-19-4492-5_11 · Cited by 1
Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsPreprint
Zhang, Y., Qu, Z., Zhang, T., Zhao, Z., Zhang, Y., & Gu, K. (2023) · Research Square · doi:10.21203/rs.3.rs-2494743/v1
Immune Checkpoint Blockade Response Biomarkers
Garrido-Barros, M., Cháves, P., & Barragán, I. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_160-1
Gut Microbiota and Host Immune System in Cancer
Sunita, P., Pattanayak, S. P., Ranjan, G., & Bose, P. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815124781123030004
Soil intake modifies the gut microbiota and alleviates ovalbumin-induced mice asthma inflammationPreprint
Li, M., Li, N., Dong, Y., Zhang, H., Bai, Z., Zhang, R., Fei, Z., Zhu, W., Xiao, P., Sun, X. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.31.543010
“Similarly, the Rikenellaceae_RC9_gut group is positively correlated with butyric and valeric acid and can alleviate colitis symptoms by stimulating Treg cell differentiation(33,34).”
BackgroundSystemic Metabolic Depletion of Intestine Microbiome Undermines Melanoma Immunotherapy EffectivenessPreprint
Zakharevich, N. V., Morozov, M. D., Kanaeva, V. A., Ivanov, A. B., Игоревич, У. В., Klimina, K. M., & Olekhnovich, E. I. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.09.561540
“It is noteworthy that the composition of microbiota not only influences the effectiveness of immunotherapy but also impacts the frequency of associated side effects [14].”
Poschel, D. B., Klement, J. D., Merting, A. D., Lu, C.-W., Zhao, Y., Yang, D.-F., Xiao, W., Zhu, H., Rajeshwari, P., Toscano, M., et al. (2023) · bioRxiv · doi:10.1101/2023.10.12.562132
Chen, H., Gao, Y., Chen, T., He, Y., Ping, L., Huang, C., & Huang, H. (2023) · Research Square · doi:10.21203/rs.3.rs-3733715/v1
The Role of the Microbiome in Immune Response
Conrad, M. A., Sullivan, K. E., & Kelsen, J. R. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch27 · Cited by 1
de Ruijter, L. K. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.952617592
Chen, Y., Liu, Y., Wang, Y., Chen, X., Wang, C., Chen, X., Yuan, X., Liu, L., Yang, J., & Zhou, X. (2022) · Figshare · doi:10.6084/m9.figshare.17799735
Gram Negative Bacteria Key Role in the Therapy of Cancer
Abaidullah, A., Sohail, F., Faryad, S., Hussain, M. S., Nadeem, A., Naeem, D., Hussain, M. S., Bhatti, S. A., Sohail, S., Ain, A. Q. U., et al. (2022) · Austin Journal of Microbiology · doi:10.26420/austinjmicrobiol.2022.1038
Cogrossi, L. L., Zordan, P., Grioni, M., Tosi, A., RIZZO, N., Policastro, A., Mattorre, B., Lorenzoni, M., Meregalli, G., Sisti, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.08.590282
Disputes and Challenges of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4910-0
Microbiome and colorectal cancer drug resistance
Miya, T. V., Belancio, V. P., & Dlamini, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-33475-7.00016-0
Macias-Gamero, I. (2024) · Springer eBooks · doi:10.1007/978-3-031-65650-7_9
Morikawa, R., Nitta, K., Yasuda, S., Kano, Y., Noji, R., Aoyama, S., Sato, S., Ikeda, S., Okamoto, R., Nagata, M., et al. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2443955
“For instance, microbiome analysis may become a valuable diagnostic tool, given reports linking specific bacteria to GI-irAEs [27].”
Microbiota in Breast Cancer: A Need for Further Knowledge
Akdeniz, D. D. (2024) · Springer eBooks · doi:10.1007/978-3-031-75480-7_33
Colitis Following Immune Checkpoint Inhibitor Therapy
Shatila, M., Varatharajalu, K., DuPont, H. L., Jenq, R. R., Carbonnel, F., Hanauer, S. B., Thomas, A. S., & Wang, Y. (2025) · Springer eBooks · doi:10.1007/978-3-031-83533-9_14
You, L., Zhai, J., Xin, Z., Na, F., Yang, W., Li, J., Song, J., Bai, L., Zhou, X., Ying, B., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5270149
Nicola, C., Pédard, M., Dubois, M., Desrues, L., Neveu, P., Riou, G., Johnston, I., Kleouforo, P. D., Lecras, P., Vaudry, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.03.673981
Siegel, R., Schlosser‐Hupf, S., Müller-Schilling, M., Kharroubi, S. A., Gessner, A., & El‐Najjar, N. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1652957
“The impact of drugs like 5-FU or cephalosporins on the microbiome is substantial and often underappreciated, exerting signi fi cant in fl uence on infections, tumor therapy, and the manifestation of (toxic) side effects (Dubin et al., 2016; Hobson et al., 2022).”
Gastrointestinal Side Effects of Anticancer Therapy
Uranga, J. A., Nurgali, K., & Abalo, R. (2025) · Springer eBooks · doi:10.1007/978-3-032-00775-9_343
Immune Checkpoint Blockade Response Biomarkers
Garrido-Barros, M., Cháves, P., & Barragán, I. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_160
Colon chaos: when drugs turn against your gut
Shatila, M., Wang, Y., & Thomas, A. S. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001142 · Cited by 1
Abbasifard, M., Taghipoor, M., Talab, M. K., & Khorramdelazad, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04040-1 · Cited by 1
“T cell repertoire diversity and gut micro-biome composition, specifically the enrichment of Faeca-libacterium and Bacteroidetes , were correlated with the incidence and resistance of irAEs [232, 233].”
Gastrointestinal complications of immune checkpoint Inhibitor therapy
Carbonnel, F., Martin, A., Marthey, L., Bellanger, C., Bou-Farah, R., Boytchev, I., Abdallah, R., Amiot, A., & Meyer, A. (2025) · La Presse Médicale · doi:10.1016/j.lpm.2025.104326
Usyk, M., Pandey, A., Hayes, R. B., Moran, U., Pavlick, A., Osman, I., Weber, J. S., & Ahn, J. (2021) · Figshare · doi:10.6084/m9.figshare.16800470
Jia, X.-H., Geng, L.-Y., Jiang, P.-P., Xu, H., Nan, K.-J., Yao, Y., Jiang, L.-L., Sun, H., Qin, T.-J., & Guo, H. (2020) · Figshare · doi:10.6084/m9.figshare.13468451
Thompson, N., Stewart, G. D., Welsh, S. J., Doherty, G. J., Robinson, M. J., Neville, B. A., Vervier, K., Harris, S. R., Adams, D. J., Dalchau, K. M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19028877
Liu, B., Liu, Z., Jiang, T., Gu, X., Yin, X., Cai, Z., Zou, X., Dai, L., & Zhang, B. (2024) · Figshare · doi:10.6084/m9.figshare.26692108
Liu, B., Liu, Z., Jiang, T., Gu, X., Yin, X., Cai, Z., Zou, X., Dai, L., & Zhang, B. (2024) · Figshare · doi:10.6084/m9.figshare.26692111
Hu, M., Lin, X., Sun, T., Shao, X., Huang, X., Weiwei, D., Guo, M., Zhu, X., Zhou, Y., Tong, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669787
Thompson, N., Stewart, G. D., Welsh, S. J., Doherty, G. J., Robinson, M. J., Neville, B. A., Vervier, K., Harris, S. R., Adams, D. J., Dalchau, K. M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19028874
Jia, X.-H., Geng, L.-Y., Jiang, P.-P., Xu, H., Nan, K.-J., Yao, Y., Jiang, L.-L., Sun, H., Qin, T.-J., & Guo, H. (2020) · Figshare · doi:10.6084/m9.figshare.13468447
Thompson, N., Stewart, G. D., Welsh, S. J., Doherty, G. J., Robinson, M. J., Neville, B. A., Vervier, K., Harris, S. R., Adams, D. J., Dalchau, K. M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19028880
Hu, M., Lin, X., Sun, T., Shao, X., Huang, X., Weiwei, D., Guo, M., Zhu, X., Zhou, Y., Tong, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26669790
Villalona-Calero, M. A., Diaz, J. P., Duan, W., Diaz, Z., Schroeder, E. D., Aparo, S., Gatcliffe, T. A., Albrecht, F., Venkatappa, S. A., Guardiola, V., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19993906
Ji, Y.-M., Qin, Y.-H., Lv, Y., Xiao, S.-Y., Dong, Y., Hu, Z.-S., Cui, P.-F., Li, T., Cui, X., & Hu, Y. (2026) · Clinical Medicine Insights Oncology · doi:10.1177/11795549251413304 · Cited by 2
“21-23 In addition, elevated gastrointestinal microbiota diversity 24 and increased serum lactate dehydrogenase (LDH) levels 25 have been associated with irAEs.”
Chen, W.-W., Li, S.-C., Yin, Q., Xu, M.-L., Zhang, J.-J., Zhao, X.-R., Xing, P.-F., Kong, Y.-H., & Zhang, L.-Y. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04292-w · Cited by 1
“Preliminary progress has been achieved in predicting AEs of RT combined with immunotherapy, exploring various potential factors including circulating biomarkers, genetic susceptibility, and gut microbiome [7–9].”
Gut microbiome in integrative oncology
Lacey, J., Stringer, A. M., Cross, C., & Wardill, H. R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30194-0.00004-7
You, L., Zhai, J., Xin, Z., Na, F., Wen, Y., Li, J., Song, J., Bai, L., Zhou, X., Ying, B., et al. (2026) · Thoracic Cancer · doi:10.1111/1759-7714.70265 · Cited by 1
Role du microbiote intestinal et avec anticorps anti-PD1 induit immunesurveillance du cancer du rein
Derosa, L. (2019) · theses.fr (ABES) · doi:10.70675/e3d7f456z3645z487az8659zc864d2b57698 · Cited by 1
Anquetil, C. (2021) · theses.fr (ABES) · doi:10.70675/dce475d2z4b83z4647z85aczea2eb971762b
Un nouveau monde microbien chez l’homme : les candidate phyla radiation (CPR)
Naud, S. (2021) · theses.fr (ABES) · doi:10.70675/2c6ab74fz802bz4a59z8eb9z97ba8ac4edd6
Geiger, M. (2023) · theses.fr (ABES) · doi:10.70675/47f0726dz445fz4a67zb320z7cb92751b601 · Cited by 1
Annotation computationnelle de génomes : des organismes uniques aux communautés complexes
Strozzi, F. (2024) · theses.fr (ABES) · doi:10.70675/c9da71c3zac1cz426fz8f3az8a3c7fcf3c17
Marcos-Kovandzic, L. (2024) · theses.fr (ABES) · doi:10.70675/3bde4b45z23ecz4b69zb90dzabccd7cd7fca
Gut microbiome modulates carcinogenesis, immunotherapy efficacy and treatment resistance
Sunny, G., Patnaik, A., & Yadav, R. (2026) · Discover Medicine · doi:10.1007/s44337-026-00593-w
Hu, N., Wang, Z., Liu, M., Guo, D., Jiang, C., Chen, Y., Zhang, Z., Bai, M., Cheng, B., Hsu, J. C., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1780459 · Cited by 4
Zheng, H., Lai, C., Liu, F., & Luo, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1817557
“Conversely, another study on ipilimumab-treated metastatic melanoma found increased abundance of Bacteroidetes phylum Bacteroides — particularly B. thetaiotaomicron and B. fragilis — correlated with resistance to ICI-induced colitis (85, 87).”
Gut Microbiota: A Potential Role in Modulating Carcinogenesis and Response to Anti‐Cancer Therapies
Yehualashet, A. S., Fersha, E. T., Yikna, B. B., & Ayenew, K. D. (2026) · Cancer Reports · doi:10.1002/cnr2.70585
“The gut microbiota is also related to ICI induced colitis [93].”
Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Associated Sicca Syndrome
Balbach, M. L., & Johnson, D. B. (2026) · Cancers · doi:10.3390/cancers18111836
The role of gut microbiota in cancer development and translational modulation strategies
Bai, X., Kang, X., & Wong, S. H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40306-4.00017-x
Operationalizing microbiome ecology in cancer care
Xavier, J. B. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.05.022
Gouveia, L., Serpa, J., & Mendes, C. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_3
Zheng, X., He, Y., Lin, W., & Sia, C. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-163
Zhang, Y., Wang, S., Chang, S., Li, Y., Dang, Y., & Wang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1803970 · Cited by 1
“This paradigm has been supported by a prospective cohort study (69) that employed 16S rRNA sequencing in patients with melanoma treated with ipilimumab (anti-CTLA-4).”
Liang, W., He, S., Tao, H., Lv, Y., Chen, X., & Peng, L. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c15493
Zhao, Y., Wen, Y., Yin, D., Yang, F., Zhong, Y., & Hu, J. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153708
Microbiome testing in gastrointestinal cancers: From microbial signatures to clinical translation
Nikitina, D., Morkūnas, E., Šabanas, P., Jonaitis, P., Urbonas, T., Gedgaudiene, G., Gedgaudas, R., Kupčinskienė, K., Macas, A., Simenas, Š., et al. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102127
Xiong, L., Huang, J., Liu, Q., Xia, H., Zhu, N., Xiang, W., Xu, W., Dong, Y., Zhu, R., Han, Y., et al. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101857
“4–6 However, the specific dysbiosis-associated metabolic shifts that initiate early mucosal damage remain poorly defined.”
Kleinberger, M., Starzer, A. M., Tomasich, E., Berger, J. M., Sunder-Plassmann, V., Gottmann, L., Henao, I. S., Korpan, M., Fuerst, J., Vladić, N., et al. (2026) · Clinical and Translational Discovery · doi:10.1002/ctd2.70156
Alotaibi, B. S. (2026) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-026-00107-w
“It was reported that ipilimumab-mediated intestinal toxicity in melanoma patients was found to be linked with GM-mediated synthesis of vitamin B and transport of polyamine (Dubin et al. 2016).”
Yuan, R., Lan, Y., Wu, M., & Lu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1857147 · Cited by 1
“The microbiome ’ s ecological balance also governs irAE risk (112, 113).”
Adam, M., Venugopal, A., Almohana, A., Awadallah, M., Purohit, P., Abid, A., Jose, E., Rajendiran, A., Banka, P., Ilipilla, C., et al. (2026) · Cell Cycle · doi:10.1080/15384101.2026.2725418
Zhou, J., Jingzhi, W., & Liu, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1875485
“Studies have found that a relatively high abundance of Bacteroidetes may be associated with a reduced risk of colitis irAE, while a microbiome rich in Firmicutes is associated with a higher incidence of colitis in some studies (Zhang et al., 2023; Dubin et al., 2016).”
B cell-guided inflammatory cascade perpetuates ICI-mediated colitis
Turner, N., Keam, S., Abdel‐Wahab, N., Colunga-Minutti, J., Trejo, C. A., Kugeratski, F. G., Pilato, M. D., Gutierrez, J. M. S., Haymaker, C., Shalapour, S., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117969
Nanoparticle pharmacomicrobiomics: Reprogramming the microbiome–immune axis for cancer immunotherapy
Siddiqua, K. S., Farooqui, S. A., Zhang, Y., Wang, L., Zhang, G., Jiang, F., & 文庭池 (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108481
Gut microbiome in immuno-oncology: potential for clinical exploitation
Margarita, E., Saito, K., Bisegna, P., Ferrari, M., Valeriani, E., Guerrieri, M., Funaro, B., Feliciani, D., Gasbarrini, A., Porcari, S., et al. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102143
Cancer pharmacomicrobiomics: Targeting microbiota to optimize cancer therapy outcomes
Punuri, S. V., Dagar, W., Vodnala, S., Bhyan, B., & Jangra, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33206-7.00011-x
Cancer and the microbiome: from association to intervention
Moradi, A., Winayak, R., & Pal, S. K. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00326-8
The Gut–Prostate Axis: Mechanistic Insights and Nanotechnology Driven Therapeutic Strategies
Mansour, R. M., Salah, A. N., Mageed, S. S. A., El-Sayyad, G. S., Rizk, N. I., Gaballah, M. S. A., zakaria, G., Abdelaziz, M. M., Fahmy, H. A., Shaker, A. A. S., et al. (2026) · Comprehensive physiology · doi:10.1002/cph4.70274
Cancer Immunotherapy and Toxicity: Biomarkers, Mechanisms and Translational Insights
Lohinai, Z., & Biswas, A. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1017474
Host determinants of immune-related adverse events during immune checkpoint inhibition
Alwithenani, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1941544
“…et al., 2022; Akturk et al., 2022), the baseline circulating immune state, in particular activated CD4 memory T-cell abundance and TCR diversity (Lozano et al., 2022), gut microbiome composition (Chaput et al., 2017; Dubin et al., 2016), and clinical history led by pre-existing autoimmune disease.”
Ciappina, G., Maltese, T., Mauro, G. D., Fiorentino, V., Ieni, A., Ottaiano, A., Simone, C., Consolo, P., Pollicino, T., & Berretta, M. (2026) · Cancer Control · doi:10.1177/10732748261500279
Wu, Y., & Fan, W. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105654
Lifestyle-induced regulatory T cell fragility primes adverse events after immune checkpoint blockade
Patra, D., Wolfgang, K., Ye, C., Rigatti, L. H., Ertwine, K. M., Morder, K. M., Jana, J. A., Baral, I., Hurd, D. E., Bossong, K., et al. (2026) · Cell · doi:10.1016/j.cell.2026.09.055
Antibiotics and outcomes of cancer immunotherapy: An updated meta-analysis and clinical applications
Porcari, S., Bolte, L. A., Björk, J. R., Elkrief, A., Derosa, L., Ferrari, M., Pezzullo, A. M., Severino, A., Fusco, W. G., Messaoudene, M., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.09.012
Metadata
- Authors
- Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., Pamer, E. G., & Wolchok, J. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Broad Institute (US)
- Corresponding author
- Pamer, Eric G.
- Wolchok, Jedd D.
- ORCID
- Venue
- Nature Communications
- Published
- 2016-02-02
- Volume
- 7
- Issue
- 1
- Pages
- 10391-10391
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4740747
- OpenAlex
- W2275606382
- Cited by
- 987
- References
- 40
- Citations by year
- 2026: 56 · 2025: 76 · 2024: 83 · 2023: 117 · 2022: 145 · 2021: 128 · 2020: 131 · 2019: 112 · 2018: 71 · 2017: 48 · 2016: 19
- FWCI
- 43.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bristol-Myers Squibb
- Memorial Sloan-Kettering Cancer Center (P30 CA008748)
- Tow Foundation
- National Institutes of Health
- Weill Cornell Medical College
- National Cancer Institute (P30CA008748)
- National Institute of General Medical Sciences (T32GM007739)
- National Institute of Allergy and Infectious Diseases (R01 AI42135, R01AI042135)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- ipilimumab, CTLA-4, metastatic melanoma, gut microbiota, Bacteroidetes, immune-related adverse events, cancer immunotherapy, polyamine transport, B vitamin biosynthesis, biomarkers, inflammatory bowel disease
- MeSH terms
- Gastrointestinal Microbiome, Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Bacteroidaceae, Colitis, Female, Humans, Male, Melanoma, Middle Aged, Prospective Studies, Risk Factors, RNA, Ribosomal, 16S, Skin Neoplasms, Sequence Analysis, RNA, Bacteroidetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.